A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker

A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker

Recent studies with nivolumab (a monoclonal antibody against programmed cell death 1 [PD-1] receptor) have shown promise non-small-cell lung cancer (NSCLC) treatment. To review available clinical trials data in order to assess nivolumab efficacy and the role of tumoral PDL-1 expression as a biomarke...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Immunotherapy 2016-09, Vol.8 (9), p.1011-1019
Hauptverfasser: Aguiar, Pedro N, Santoro, Ilka Lopes, Tadokoro, Hakaru, de Lima Lopes, Gilberto, Filardi, Bruno Andraus, Oliveira, Pedro, Castelo-Branco, Pedro, Mountzios, Giannis, de Mello, Ramon Andrade
Format: Artikel
Sprache:eng
Schlagworte:
Antibodies, Monoclonal - therapeutic use
Antineoplastic Agents - therapeutic use
Apoptosis
B7-H1 Antigen - genetics
B7-H1 Antigen - metabolism
Bias
Biomarkers
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Cancer therapies
Carcinoma, Non-Small-Cell Lung - diagnosis
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - mortality
Cell death
Chemotherapy
Clinical outcomes
Clinical trials
Collaboration
Handbooks
Histology
Humans
Immune system
Immunotherapy
Kinases
Lung cancer
Meta-analysis
Monoclonal antibodies
Mutation
nivolumab
Non-small cell lung carcinoma
Patients
PD-1 protein
PD-L1 protein
Predictive Value of Tests
Prognosis
Response rates
Small cell lung carcinoma
Studies
Survival Analysis
Targeted cancer therapy
Taxoids - therapeutic use
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Recent studies with nivolumab (a monoclonal antibody against programmed cell death 1 [PD-1] receptor) have shown promise non-small-cell lung cancer (NSCLC) treatment. To review available clinical trials data in order to assess nivolumab efficacy and the role of tumoral PDL-1 expression as a biomarker. Nine eligible studies included 2102 patients. In the second line setting, nivolumab achieved a 1-year survival rate of 41%; and in the first line, a 1-year survival rate of 76%. For those with PD-L1 expression
ISSN:1750-743X
1750-7448
DOI:10.2217/imt-2016-0032